STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer (2016)
- Authors:
- Autor USP: SQUIRE, JEREMY ANDREW - FMRP
- Unidade: FMRP
- DOI: 10.1002/cjp2.55
- Subjects: NEOPLASIAS OVARIANAS; QUIMIOTERAPIA; IMUNIDADE
- Keywords: Interferon; Intratumoural CD8+ T cell; Ovarian cancer; Chemoresistance; STAT1
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2016
- Source:
- Título: The Journal of Pathology : Clinical Research
- ISSN: 2056-4538
- Volume/Número/Paginação/Ano: v. 2, n. 4, p. 259-270, 2016
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
AU, Katrina K. et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, v. 2, n. 4, p. 259-270, 2016Tradução . . Disponível em: https://doi.org/10.1002/cjp2.55. Acesso em: 27 dez. 2025. -
APA
Au, K. K., Page, C. L., Ren, R., Meunier, L., Clément, I., Tyrishkin, kathrin, et al. (2016). STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, 2( 4), 259-270. doi:10.1002/cjp2.55 -
NLM
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1002/cjp2.55 -
Vancouver
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1002/cjp2.55 - Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
- Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
- Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
- Application of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for detecting PTEN loss in diagnostic prostate cancer needle biopsies
- In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in sity hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
- Extracellular vesicles: evolving factors in stem cell biology
- The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
- Quantitative assessment of PTEN loss (qPTEN) is strongly associated with biochemical recurrence and may improve treatment decisions after surgery
Informações sobre o DOI: 10.1002/cjp2.55 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
